CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC

1:15-cv-00510

Overview

Case Number 1:15-cv-00510
Filing Date 2015-06-17
Status Terminated
Termination Date 2017-04-27
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:0145
Jury Demand None

Parties

Defendant

Amneal Pharmaceuticals LLC Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Meda Pharmaceuticals Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 8 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials 1 proceeding
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (8): πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (1 found):
PTAB: 1
USPTO PTAB Trial 2014-05-07
IPR2014-00731

Impax Laboratories, Inc. v. Meda Pharmaceuticals Inc.

U.S. Continuation Sibling (8071073)
Status: Institution Denied
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8071073
Compositions comprising azelastine and methods of use thereof
Filed: 2005-11-22
Issued: 2011-12-06
Active (1.5 yrs remaining) +925d PTA
Expires: 2028-06-04
US8518919
Compositions comprising azelastine and methods of use thereof
Filed: 2011-11-10
Issued: 2013-08-27
Active (5.0 yrs remaining)
Expires: 2031-11-10

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+925 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(20 total)
Pleading / Complaint

COMPLAINT filed against Boehringer Ingelheim Roxane, Inc., Roxane Laboratories, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 23672.) - filed by Meda Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(nmb) (Entered: 06/18/2015)

Entry #1 • 2015-06-17
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmb) (Entered: 06/18/2015)

Entry #2 • 2015-06-17
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 5/8/15. Date of Expiration of Patent: 6/4/28, 11/22/25.Thirty Month Stay Deadline: 11/8/2017. (nmb) (Entered: 06/18/2015)

Entry #3 • 2015-06-17
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,071,073; 8,518,919;. (nmb) (Entered: 06/18/2015)

Entry #4 • 2015-06-17
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Meda AB for Meda Pharmaceuticals Inc. filed by Meda Pharmaceuticals Inc.. (nmb) (Entered: 06/18/2015)

Entry #5 • 2015-06-17
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc